Association between beta-1-adrenoceptor blockade and risk of Raynaud’s phenomenon: Mendelian randomisation study
We found no genetic evidence to support a causal association between beta-1-adrenoceptor blockade and Raynaud's phenomenon risk in either direction. Randomised controlled trials are required to confirm the safety of beta-1-adrenoceptor blockers in people with Raynaud's phenomenon.
Authors
- Michael Hughes (ORCID: https://orcid.org/0000-0003-1660-8689)
- Sizheng Steven Zhao (ORCID: https://orcid.org/0000-0002-3558-7353)
- Kathryn Coulson (ORCID: https://orcid.org/0000-0001-6461-5192)
- David M. Hughes (ORCID: https://orcid.org/0000-0002-1287-9994)
- Kira Rogers
- J. Williams (ORCID: https://orcid.org/0009-0006-3737-557X)
Institutions
- University of Leeds (GB)
- University of Liverpool (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Manchester Academic Health Science Centre (GB)
- St James's University Hospital (GB)
- University of Manchester (GB)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
Publication Details
- Journal
- Journal of Scleroderma and Related Disorders
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1177/23971983241312543
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Versus Arthritis